Novel synthetic bone graft may have higher spinal fusion rate vs. bone autograft
Key takeaways:
- A novel synthetic bone graft showed noninferiority to autograft in posterolateral spinal fusion.
- The synthetic graft also diminished the effects of smoking on surgical outcomes.
SAN DIEGO — A novel synthetic bone graft utilizing submicron-sized needle-shaped surface biphasic calcium phosphate may be superior to bone autograft for instrumented posterolateral spinal fusion, according to results presented here.
Robert K. Eastlack, MD, FAAOS, head of the division of spine surgery at Scripps Clinic in La Jolla, Calif., and colleagues enrolled 100 patients indicated for instrumented posterolateral spinal fusion of one to six levels from T10-S2 in a prospective, randomized control trial to compare the surgical efficacy of a novel advanced synthetic bone graft (MagnetOs, Kuros Biosciences) vs. a bone autograft with greater than 50% iliac crest.
Patients were randomly assigned a synthetic bone graft in one side and a bone autograft on the contralateral side, Eastlack said in his presentation at the American Academy of Orthopaedic Surgeons Annual Meeting.
The primary outcome of the study was fusion rate, which was measured using CT evaluations. Eastlack and colleagues also collected patient-reported outcome measures.
According to Eastlack, the fusion rate with the synthetic graft was approximately 80% vs. approximately 50% with the bone autograft.
In addition, he said patients who were smokers had an approximately 75% fusion rate with the synthetic graft vs. approximately 30% with the bone autograft.
“There is a clear benefit of this material over iliac crest, which was considered the gold standard previously in a posterolateral fusion model,” Eastlack said.
Collapse
Read more about